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Optimizing human Treg 
immunotherapy by Treg subset 
selection and E-selectin ligand 
expression
Conor Donnelly2,4,5, Brad Dykstra2,4,6, Nandini Mondal2,4, Junning Huang1, Belinda J. 
Kaskow1, Russell Griffin2, Robert Sackstein2,3,4 & Clare Baecher-Allan1,2
While human Tregs hold immense promise for immunotherapy, their biologic variability poses 
challenges for clinical use. Here, we examined clinically-relevant activities of defined subsets of 
freshly-isolated and culture-expanded human PBMC-derived Tregs. Unlike highly suppressive 
but plastic memory Tregs (memTreg), naïve Tregs (nvTreg) exhibited the greatest proliferation, 
suppressive capacity after stimulation, and Treg lineage fidelity. Yet, unlike memTregs, nvTregs lack 
Fucosyltransferase VII and display low sLeX expression, with concomitant poor homing capacity. In vitro 
nvTreg expansion augmented their suppressive function, but did not alter the nvTreg sLeX-l°w glycome. 
However, exofucosylation of the nvTreg surface yielded high sLeX expression, promoting endothelial 
adhesion and enhanced inhibition of xenogeneic aGVHD. These data indicate that the immature Treg 
glycome is under unique regulation and that adult PBMCs can be an ideal source of autologous-derived 
therapeutic Tregs, provided that subset selection and glycan engineering are engaged to optimize both 
their immunomodulation and tropism for inflammatory sites.
The ability to achieve immunomodulation via cellular therapy offers the promise of avoiding pharmacologic 
immunosuppressants, improving the specificity of therapy and preventing toxic drug effects. Tregs represent a 
specialized subset of CD4+ T cells which co-express high levels of CD25 (interleukin-2Rα chain) and intracellular 
FoxP31, are dependent on interleukin-2 for survival2, and exert dominant tolerance via a cell contact-mediated 
mechanism of suppression3. Yet, it is important to note that Treg cells obtained from patients with various auto-
immune diseases have shown functional plasticity by transitioning into a pro-inflammatory state in which they 
secrete IFNγ or IL-174. Early preclinical studies using the Treg subset of CD4+ T cells in immunotherapy pro-
vided evidence of their ability to dampen autoimmunity and enhance tolerance to tissue transplants5,6. Models of 
hematopoietic stem cell transplantation (HSCT) have shown that the adoptive transfer of Tregs could reduce the 
incidence of acute graft-versus-host disease (aGVHD)7 while retaining the crucial graft-versus-tumor benefit of 
the allotransplant, in sharp contrast to treatments with broad immunosuppressants8. However, as Tregs are a low 
frequency population and the yield of all memory Tregs is not sufficient for clinical application9–11, an initial in 
vitro expansion is often utilized to generate Treg cellular therapeutics.
Currently, there are over 280 clinical trials utilizing the adoptive transfer of Tregs to reduce the morbidity 
related to autoimmune disease, solid organ transplantation, and allogeneic hematopoietic stem cell transplanta-
tion (clinicaltrials.gov, Nov. 13, 2017). While adoptive Treg therapy represents a promising cellular therapeutic 
in principle, many clinical trials administering Treg populations to treat aGVHD or other immunologic diseases 
have not shown the efficacy that many believe Treg therapies could deliver12. Variations in Treg isolation pro-
cedures and expansion methods, and resulting fluctuations in Treg purities, may underlie the observed lack of 
efficacy. Since Tregs are a low frequency population and clinical cellular therapeutic trials require large numbers 
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of Tregs, the trials have used Tregs that have been either enriched from large-scale leukapheresis collections 
or have been expanded with a period of in vitro stimulation. A recent report of administering autologous, in 
vitro-expanded total CD25 + CD12710 Tregs to recent onset T1D patients demonstrated safety but little effi-
cacy13, while eight of twenty patients with Crohn’s disease showed improvement after being given autologous in 
vitro-ovalbumin-expanded clonal Tr1-like Tregs and ingesting ovalbumin to theoretically activate intestinal Tregs 
in vivo14,15. Reported attempts at Treg therapy to treat aGVHD have used freshly harvested leukapheresis-derived 
cells in which only ~50% of the cells expressed Foxp310,16, ex-vivo expanded cells from adult peripheral blood11 or 
third party cord-blood9. More recent studies have shown that delivering a Treg cellular therapeutic derived from 
cord blood and expanded with CD64- and CD86- expressing K562 cells reduced the number of patients exhib-
iting grade II-IV aGVHD by 36%17, and that delivering a dose of FoxP3 + Tregs before HSCT can result in an 
increase in disease-free survival, with the caveat of higher treatment-related mortality18. Although these ongoing 
studies hold much promise, the limitations in treatment efficacy may reflect the lack of uniformity in Treg prepa-
ration with an unclear functionality of the Treg preparations.
Identifying the ideal source of Tregs is critical to optimizing the efficacy of Treg cellular therapy19. An optimal 
Treg source or subpopulation should exhibit considerable in vitro expansion capacity while maintaining high 
purity (characterized by FoxP3 expression, not simply CD25 expression), strong Treg lineage fidelity and effective 
suppressive activity. Identifying the optimal starting Treg population could minimize the outgrowth of activated, 
non-regulatory and potentially pro-inflammatory T cells during the process of in vitro (and then subsequent 
in vivo) expansion. Though magnetic bead-based methods of Treg isolation are commonly used, FACS-based 
human Treg selection is preferable as it not only maximizes purity, but also makes it possible to isolate Treg 
subsets that may differ in qualities that are, or are not, desirable in a therapeutic. Comparing the functional attrib-
utes of individual Treg subpopulations may indicate if certain subsets are prone to co-express pro-inflammatory 
cytokines and FoxP3, while other Treg populations may be predisposed to lose FoxP3 and give rise to ‘ex-Tregs” 
that express self-antigen specific TCR’s but lack suppressive activity.
Three functionally-distinct Treg subsets can be FACS-sorted by virtue of CD45RA, CD25hi, CD127 and 
HLA-DR expression20–22: (1) The HLA-DR+ effector memory Tregs (DR + mTreg)22,23 that induce immediate 
strong suppression but have low proliferative capacity and short telomeres24; (2) The less suppressive but more 
proliferative HLA-DR− memory Tregs (DR−mTreg); and (3) The least suppressive, but highly proliferative naïve 
Tregs (nvTreg), which become more suppressive with activation22. The characterization of Treg subsets for their 
capacity to function as an adoptive therapeutic, including proliferation with maintenance of lineage fidelity, 
endothelial rolling under shear forces, and capacity to undergo tissue extravasation has not been adequately 
described.
While it is evident that a Treg therapeutic should exhibit high purity and suppressive capacity, the ability of 
the infused cells to migrate into target tissues is a less obvious but similarly vital feature that can affect therapeutic 
efficacy. In fact, suboptimal tissue homing has been proposed to be a potential contributor to the poor efficacy 
reported in some Treg clinical trials25,26. The ability of lymphocytes to migrate into inflammatory sites is criti-
cally dependent on expression of a tetrasaccharide glycan motif known as sialyl-Lewis X tetra-saccharide (sLeX; 
CD15 s: NeuAc-α(2,3)-Gal-β(1,4)-[Fuc-α(1,3)]-GlcNac-R), which is displayed on glycoproteins and glycolipids 
on the lymphocyte surface. sLeX is the proto-typical binding determinant for E-selectin (CD62E), an endothelial 
molecule. sLeX can be detected by monoclonal antibodies such as CSLEX-127, or by the HECA452 monoclonal 
which detects a determinant often referred to as “cutaneous lymphocyte antigen” (CLA). CSLEX-1 is more spe-
cific for the tetrasaccharide sLeX, whereas HECA452 more broadly recognizes sLeX and its isomer sLeA, as well as 
sulfated, fucosylated type 2 lactosamines that can also function as E-selectin ligands28,29. Importantly, HECA452 
staining tracks E-selectin binding activity of cells more closely than does CSLEX-1 staining30.
E-selectin is constitutively expressed in skin and bone marrow microvessels, and is highly expressed in micro-
vascular endothelial beds at all sites of inflammation via its induction by inflammatory cytokines TNF-α and 
IL-1β31–34. The interaction between lymphocyte sLeX and endothelial E-selectin initiates a cascade of events cul-
minating in cell extravasation and tissue infiltration35. A previous study reported that freshly-isolated CD45RO+ 
memory Tregs stain with HECA452 (i.e. express CLA), bind to TNF-stimulated human endothelial cells and 
undergo transendothelial migration when tested under static conditions; in contrast, freshly-isolated CD45RA+ 
nvTregs were found to express little CLA and lacked the capacity to undergo static transendothelial migration36. 
Although these data suggest an association between effector state and migratory capacity, prior studies have not 
evaluated how in vitro activation of the HLA-DR and CD45RA defined Treg subpopulations affects their expres-
sion of sLeX and their ability to enter tissues.
In this report, we examined the suitability of different human Treg subsets to function as a potential cellu-
lar therapeutic. We undertook a direct comparison of the in vitro and in vivo functional activities of the dif-
ferent memory and naïve Treg subpopulations. Both freshly-isolated and culture-expanded human peripheral 
blood-derived Treg populations were tested for their capacity to suppress, to engage endothelium under hemo-
dynamic shear conditions, to extravasate through endothelium, to produce pro-inflammatory cytokines, and 
to proliferate with lineage fidelity. Our results indicate that the nvTreg is the Treg population that exhibits the 
ideal biological features of a Treg therapeutic. We also obtained data indicating that the recently described sLeX-hi 
effector Tregs37 show overlapping features with effector DR + mTregs. In addition, the results indicate that the 
highly suppressive memTregs should be purposefully excluded from a Treg therapeutic due to their low lineage 
fidelity, low proliferative capacity, and greater pro-inflammatory potential. Although the nvTregs natively lack 
sLeX expression, they display the sialylated lactosamine scaffolds that can be enzymatically modified by exofuco-
sylation to express the sLeX structure, thereby programming E-selectin binding and in vivo migration to inflam-
matory sites. Enforced expression of sLeX-on in vitro expanded nvTregs markedly enhanced the ability of the cells 
to inhibit in vivo xenogeneic aGVHD responses. Our results offer novel perspectives on the immunobiology of 
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Treg subsets and their capacity to localize at inflammatory sites, providing a roadmap for the future selection and 
use of Tregs in cellular immunotherapies.
Results
Heterogeneity in suppressive capacity of freshly isolated human Treg subsets. As the most basic 
requirement for a Treg cellular therapeutic is its ability to inhibit immune activation, we directly compared the 
suppressive ability of FACS-sorted nvTregs, DR + mTregs and DR−mTregs (for FACS-gating see Supplemental 
Fig. 1). FACS-sorting these functionally distinct Treg populations from ~100 ml of peripheral blood from healthy 
donors resulted in obtaining highly pure populations (based on FoxP3 staining) exhibiting marked differences in 
average yield (Fig. 1A). A typical collection of 250 × 106 PBMC yields 4 × 105 nvTregs, 3 × 105 DR− mTregs and 
0.5 × 105 DR+mTregs. To compare suppressive capacity, the sorted Treg populations were co-cultured with CFSE-
labeled CD25−/CD45RA− CD4+ T cells (mTresp) at a suboptimal, ½:1 ratio. The typical inhibition of mTresp 
proliferation/CFSE dilution that occurs when the mTresp cells are co-cultured with half as many of each type of 
Treg is shown in Fig. 1B. The sorted Treg-subsets consistently exhibited differences in suppressive ability (Fig. 1C) 
as the DR+mTregs were the most suppressive and the nvTregs exhibited the lowest suppressive capacity in co-cul-
tures stimulated with αCD3/αCD2 (top), αCD3/αCD28 (middle), or αCD3/APCs (bottom). The finding that 
ex vivo nvTregs are less suppressive than memory Tregs is consistent with previous publications that tested the 
activity of suboptimal Treg numbers38–40, but differs from reports that assayed Treg:Tresp co-cultures at the opti-
mal 1:1 ratio which usually results in memory and naïve Tregs inducing equal levels of suppression41,42.
Treg subsets exhibit significant heterogeneity in binding to vascular endothelium under hemo-
dynamic shear conditions. We next compared the ability of the different types of Tregs to bind and cross 
the endothelium as an indication of their potential capacity to migrate into target tissues in vivo. The process 
by which a T cell enters a target organ is initiated by the interaction of sLeX moieties on the T cell surface with 
endothelial cell-expressed E-selectin, and culminates in cell extravasation and tissue infiltration35. Thus, we 
assessed whether the Treg subsets differed in their expression of surface sLeX, their ability to tether and roll on 
TNFα-stimulated vascular endothelium under fluid conditions that mimic the hemodynamic shear stress of 
blood flow, and to undergo static transmigration through an endothelial monolayer.
First, we determined the capacity of each population to co-express intracellular FoxP3 and surface sLeX as 
this would likely predict the ability of a cell to traffic to sites of inflammation. As sLeX is detected more spe-
cifically by mAb CSLEX-1 (anti-CD15 s), but mAB HECA-452 staining has better correlation with E-selecting 
binding capacity30, both CD15 s and HECA452 antibodies were used to probe the different freshly-isolated Treg 
populations. Shown in Fig. 2A, the freshly-isolated blood-derived Treg subsets exhibited different patterns of 
sLeX/E-selectin-ligand expression, with CD15 s and HECA452 exhibiting highly similar binding patterns on each 
population. The staining with CD15 s or HECA452 mAbs indicated that the nvTregs exhibited the lowest expres-
sion of sLeX (~1% CD15 s and 3% HECA452 staining), followed by the DR−mTregs (34% CD15 s versus 64% 
HECA452 staining), while the vast majority of the DR+mTregs strongly expressed sLeX (~57% CD15 s and 84% 
HECA452 staining). Surprisingly, the mTresp cells expressed significantly less sLeX than either of the freshly iso-
lated memory Treg populations. Furthermore, as CD162 (PSGL1), CD44, and CD43 represent the major T-cell 
proteins that can be decorated with sLeX, the different Treg populations were also examined to determine if they 
exhibited similar levels of these proteins themselves. The relative staining pattern (Fig. 2B) indicated that although 
the DR + mTregs expressed the highest levels of each of these proteins and the highest level of CD15 s/HECA452, 
the nvTregs also highly expressed these protein scaffolds, but apparently, without the sLeX glycosylation.
As sLeX is generated via an α(1,3) linkage-specific addition of fucose to a sialo-lactosamine trisaccharide 
scaffold, we next examined whether the differential Treg expression of sLeX reflected differences in expression of 
the specific fucosyltransferases that add this specific fucose linkage, or in the expression of fucosidases that can 
cleave fucose from the cell surface. As shown in Fig. 2C, mRNA from the different freshly isolated T cell popula-
tions was examined for relative expression of α(1,3)-fucosyltransferases IV (FUT4) and VII (FUT7), along with 
fucosidase 1 (FUC1). The results indicated that, although the different subsets exhibited no difference in FUT4 
expression, FUT7 expression was significantly upregulated in both the DR+mTregs and the DR−mTregs relative 
to the nvTregs. Moreover, the nvTregs were also found to express significantly more FUC1. This combination of 
low fucosyltransferase activity and high fucosidase activity in the nvTreg would promote the observed low sLeX 
expression on these cells.
The functional capacity of these freshly isolated T cell populations to roll/adhere on TNF-α−stimulated 
HUVEC was tested on a parallel plate flow chamber apparatus that mimics the shear forces in the circulation 
(Fig. 2D). Under physiologically relevant shear (1–4 dynes/cm2), the nvTregs exhibited the lowest capacity to bind 
to E-selectin+ endothelial cells, while increasing adherence was exhibited by the memory CD4+ T cells (mTresp), 
followed by the DR− mTregs, with the highest binding activity by the DR+mTregs. The adhesive property of 
each T cell population was directly proportional to their relative expression of sLeX. Remarkably, the highly sup-
pressive, DR+mTregs exhibited the strongest binding of any tested cell type (including tumor cell lines, data not 
shown), as they resisted shear up to 8 dynes/cm2.
Lastly, the capacity of freshly isolated Treg populations to undergo the full process of static transendothelial 
migration (TEM) was tested using Boyden chambers established with monolayers of HUVEC that had been 
stimulated with TNFα to induce E-selectin expression. As indicated in Fig. 2E, the DR+mTregs exhibited the 
most efficient transmigration through HUVEC monolayers as compared to all other freshly-isolated subsets. 
Unexpectedly, although the sLeX-l°w nvTregs had the lowest TEM potential in which only ~3.8% underwent 
transmigration, the DR− mTregs that are 50% positive for sLeX also exhibited a surprisingly low TEM ability. 
Altogether, these data suggest that the DR+mTregs, which had previously been referred to as effector Tregs due to 
their rapid suppressive activity, short telomeres, and inability to proliferate22,43, are synonymous with the sLeXhi 
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Figure 1. Treg subsets exhibit distinct yields and ex vivo suppressive capacities. (A) nvTregs, DR−mTregs, and 
DR+mTregs differ in yield when FACS-sorted from fresh donor blood (n = 7). (B) Typical suppression by CFSE 
dilution, is shown for co-cultures established with CFSE labeled Tresp and half as many Tregs (5 days). (C) 
Treg co-cultures were established under different stimulation protocols in which the cells were stimulated with 
αCD3/αCD2 (top), αCD3/αCD28 (middle) or anti-CD3/APC (bottom). The DR+mTregs induced the highest 
suppression, followed by DR−mTreg and lastly by the least suppressive nvTregs. Data shown are mean ± SEM, 
and significance determined by Student’s t test, is indicated as (*P < 0.05) and (**P < 0.01). [turn scatter plots 
into bar graphs with X+/− SEM].
www.nature.com/scientificreports/
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effector Tregs that were more recently identified by Miyara et al.37. This migratory activity indicates that the max-
imally suppressive DR + mTregs have the highest potential to arrive at sites of inflammation to inhibit immune 
activation, while the other Treg subsets would be much less likely to enter the tissue. These findings further sup-
port the effector classification of DR + mTregs as they express the highest level of sLeX and exhibit the strongest 
rolling, adherence, and transmigration through endothelium.
Treg populations exhibit distinct capacities to proliferate and produce pro-inflammatory cytokines. 
We next examined whether the different Treg subsets exhibit distinct proliferation-associated features that would 
affect their suitability for selection as a cellular therapeutic. Ideally the Treg subset must be able to undergo 
marked in vitro expansion while maintaining high fidelity Treg function. Although their superior migratory 
activity and suppressive capacity suggest that the ex vivo DR+mTreg is the ideal population to harness for use in 
adoptive therapy, DR + mTregs are a rare population as they represent a minor portion (~10%) of the small circu-
lating Treg population. In addition, DR + mTregs were previously shown to have extremely short telomeres and 
lack the capacity to proliferate22, indicating that they may not have the capacity to undergo sufficient expansion 
for therapeutic consideration.
In assessing the proliferative response of each FACS-sorted Treg population, the purity and lineage fidelity 
of each Treg population was measured after in vitro culture/expansion by staining for high expression of FoxP3, 
evaluating functional in vitro suppression, and testing whether the expanded cells express pro-inflammatory 
Figure 2. DR + mTregs and nvTregs differ in their capacity to express sLex, to adhere to endothelium under 
shear, and to undergo endothelial transmigration. Freshly isolated cells were stained with (A) CD15s or 
HECA452 (for surface sLex), or FMO control, and intracellular anti-FoxP3; or (B) surface expression of CD43, 
CD44 and PSGL1 (CD162). FACs sorted fresh cells were examined for their (C) relative gene expression of 
fucosyltransferases IV and VII and fucosidase 1α (FUC1) by RT-PCR; (D) capacity to roll and adhere to 
activated endothelium in the presence of increasing shear stress from 0.5–8 dynes/cm2, and their ability to (E) 
migrate through a TNFα-activated monolayer endothelial towards a CXCR4 gradient using Boyden chambers 
with SDF-1 (125 ng/ml) in the lower chamber (12 hours). Rolling and extravasation experiments were repeated 
with cells from three separate healthy donors. Data are shown as mean ± SEM. Significance was determined by 
Student’s t test and indicated as (*P < 0.05), (**P < 0.01), and (***P < 0.001).
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cytokines. A reduction in the frequency of cells expressing FoxP3hi in the expanded populations would indicate 
either low fidelity to the Treg lineage (generation of ex-Tregs) or the expansion of contaminating non-Tregs. 
By counting and staining cells from each stimulated population, the nvTregs exhibited significantly higher 
expansion potential than either memory subset, while the DR+mTregs exhibited almost no growth, as expected 
(Fig. 3A). On average, after fourteen days of culture, the stimulation resulted in expansions of more than 200-fold 
(75 × 106) for the nvTregs, 30-fold (10 × 106) for the DR−mTregs, and less than 10-fold for the DR+mTregs. 
Furthermore, while the nvTreg and DR−mTreg consistently retained their high levels of purity, the DR+mTreg 
exhibited a surprisingly high loss of FoxP3 as just over 50% of the expanded DR + mTregs expressed FoxP3 
(Fig. 3B). Thus although greater than 95% of the DR + mTregs initially expressed FoxP3, these data suggest that 
the cells in the stimulated DR + mTreg cultures arise from the outgrowth of non-regulatory contaminants or that 
these cells transition to ex-Tregs and lose FoxP3. Next, we compared the suppressive capacity of those expanded 
Treg populations that exhibited high lineage fidelity, the nvTregs and DR−mTregs. Strikingly, as shown in Fig. 3C, 
in contrast to the low suppressive activity of the freshly isolated blood nvTregs, the expanded nvTregs exhibited 
a markedly enhanced suppressive capacity that was even more profound than that exhibited by the expanded 
DR−mTregs.
As a small fraction of human Tregs have been shown to have the capacity to transition into potentially 
pro-inflammatory FoxP3 + cells that express either IFNγ or IL-17, the expanded high-fidelity DR−mTreg 
and nvTreg populations were tested to determine if they differed in their propensity to produce these 
pro-inflammatory cytokines. The ability to produce pro-inflammatory cytokines was reported to be a prop-
erty of memory Tregs isolated from patients with autoimmune diseases, and has been suggested to poten-
tially be an early indicator of decreasing lineage fidelity44,45. As shown in Fig. 3D (with replicates shown in 
Fig. 3E), the expanded DR−mTregs contained a low but consistent number of cells that co-expressed both 
IL-17 and FoxP3, while the expanded nvTregs did not co-express FoxP3 and IL-17 (IFNγ was not detected). 
Altogether, these data suggest the nvTregs exhibit greater fidelity to the suppressive Treg lineage than the 
DR−mTreg population.
Figure 3. The different Treg subsets exhibit unique capacities to undergo in vitro expansion with maintained 
FoxP3 expression and suppressive activity. (A) The number of T cells that were produced after a 14d in vitro 
stimulation is shown (n = 3). The expanded T cell populations were tested for (B) expression of intracellular 
FoxP3 to indicate purity; and (C) for their ability to suppress CFSE labeled mTresp when co-cultured at a 
1:1/2 (mTresp:Treg) ratio with αCD3/APC stimulation. (D) Shows representative intracellular staining of the 
expanded Tregs for co-expression of FoxP3 and IL-17. (E) The frequency of IL-17 producing, FoxP3+ cells 
in the DR−mTreg versus the nvTreg populations (n = 4) is shown. Data shown are mean ± SEM. Significance, 
determined by Student’s t test, is indicated by (*P < 0.05), (**P < 0.01), and (***P < 0.001).
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Exofucosylation is required to create selectin ligands on expanded nvTregs. As stimulated 
nvTregs exhibit the greatest fold expansion and highest yield, superior suppressive activity and maintained 
high Treg fidelity as compared to the other Treg subsets, we next asked whether the in vitro-expanded nvTregs 
would also exhibit an increased ability to undergo TEM in the absence of shear. Thus, we first tested whether the 
expanded nvTreg population underwent TEM in the same static migration assay described previously. As shown 
in Fig. 4A, a significantly higher frequency of expanded nvTregs underwent TEM as compared to the freshly iso-
lated nvTregs. Surprisingly, the TEM capacity exhibited by the expanded nvTregs was even greater than the TEM 
capacity exhibited by the freshly-isolated “effector” DR+mTregs. As a result, we next examined whether mole-
cules that are known to be involved in TEM are more highly expressed on the surface of the nvTreg after in vitro 
expansion. As shown in Fig. 4B, the expanded nvTregs were found to exhibit both a substantial increase in surface 
expression of CXCR4, which confers migratory responsiveness to SDF-1, and maintained their high expression 
of the integrin VLA-4, which interacts with endothelial cell VCAM-1 (Fig. 4C). (All regulatory and effector T cell 
populations expressed LFA-1, as shown in Supp. Fig. 2A).
We next asked whether the expression of sLeX was also increased on the surface of the in vitro expanded 
nvTregs. However, upon staining for surface expression of sLeX, the expanded nvTregs exhibited only a mod-
est increase in expression of sLeX (12% by CD15 s, 22% by HECA452) as compared to freshly isolated nvTregs 
(Fig. 4D,E). As expression of sLeX can be regulated at the level of reduced installation or enhanced cleavage of 
fucose on the cell surface, we examined whether the expanded nvTregs exhibited a unique expression profile of 
the transcripts that encode the enzymes that regulate levels of cell surface α(1,3)-fucosylations. By real-time PCR, 
we found that the expanded nvTregs did not express mRNA for FUT7 (Fig. 4F) and maintained the high expres-
sion of the fucosidase, FUC1, typically found in freshly isolated blood nvTregs (Supp. Fig. 2B). These data indicate 
that the capacity to express sLeX, which is prevalent in memory CD4 T cells populations, is not simply acquired 
by TCR stimulation in the nvTreg population.
As this extremely low expression of sLeX on expanded nvTregs would result in poor binding to endothelial 
cells under shear and translate into reduced capacity to suppress tissue inflammation if introduced as a cellular 
Figure 4. Exofucosylation increases expression of selectin ligands on nvTregs and their endothelial adherence. 
Freshly isolated nvTregs and effector DR+mTregs, and 14-day in vitro expanded nvTregs were tested for their 
ability to (A) undergo static transendothelial migration (TEM) towards SDF-1 in a Boyden Chamber assay, 
and to express surface (B) CXCR4, and (C) VLA-4. All T cell subsets, isolated from three donors, were stained 
pre- and post-expansion to determine expression of sLeX as detected by (D) HECA452 or (E) CD15 s. (F) 
Pre- and post- ex vivo expanded nvTregs were examined for their relative expression of FUT7 RNA by RT-
PCR. (G) Buffer- or fucosyltransferase VII-treated expanded nvTregs were stained to determine HECA452/
sLex expression. (H) The proteins that bind mE-selectin-Ig in buffer- or FTVII-treated expanded nvTregs were 
identified by performing sequential immunoprecipitation on lysates with anti-CD44, anti-PSGL-1, and then 
anti-CD43, and detecting the proteins that bound mE-selectin-Ig by western blotting. The blot in Fig. 4H was 
not cropped as the samples were run in the order as shown. (I) Buffer-treated and FTVII-treated expanded 
nvTregs, and freshly isolated nvTregs were examined for their ability to roll and adhere to endothelium in the 
presence of dynamic shear forces. Data shown are mean ± SEM. Significance, determined by Student’s t test, is 
indicated by (*P < 0.05), (**P < 0.01), and (***P < 0.001).
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therapeutic, we asked whether enforcing expression of sLeX on the surface of the expanded nvTregs would aug-
ment their ability to bind to activated endothelium and thus enhance their potential therapeutic efficacy. If the 
expanded nvTregs expressed the correct acceptor carbohydrate moieties (sialyl-lactosamine trisaccharides), the 
addition of fucose in the correct α(1,3)-linkage could produce sLeX. To test this notion, viable expanded nvTregs 
were incubated with a purified, recombinant FTVII enzyme (from R&D Systems/Biotechne), and then stained 
for sLeX to determine if fucose moieties were added in the correct configuration to the cell surface. The stain-
ing results indicated that the FTVII-treated, expanded nvTregs exhibited a dramatically increased expression 
of sLeX relative to buffer-treated cells (90% from 12%) (Fig. 4G). In addition, not only did the enzymatically 
treated, expanded nvTregs exhibit increased sLeX expression as indicated by HECA452 staining, but also the cells 
exhibited a markedly increased capacity to bind E-selectin (when stained under fluid shear conditions, Supp. 
Figure 2C). As FTVII treatment was able to generate sLeX moieties on the expanded nvTreg, this indicates that 
the expanded nvTregs express the appropriate scaffold acceptor trisaccharides but lack sLeX due to an absence of 
α(1,3)-fucose modifications.
The molecules on the expanded nvTregs that were targeted by the FTVII treatment were next examined. 
FTVII enzyme treatment could generate sLeX determinants on either protein or lipid. However, since a limited 
pronase treatment of samples of FTVII treated expanded nvTregs effectively removed cell surface sLeX, it is appar-
ent that the FTVII treatment generated E-selectin ligands on surface glycoproteins (Supp. Fig. 3A). The identity 
of the proteins modified by FTVII treatment of expanded nvTregs was determined by performing exhaustive, 
sequential immuno-precipitation of known sLeX containing proteins from lysates of FTVII treated, expanded 
nvTregs. The specific immunoprecipitated proteins that expressed sLeX on the expanded nvTregs after FTVII 
treatment were identified by their capacity to interact with E-selectin by western blot (Fig. 4H). In analyzing 
all E-selectin binding proteins in the initial lysates, buffer-treated cells showed a single faint E-selectin-reactive 
band at ~120 kDa, while the FTVII-treated cells exhibited intense E-selectin-binding proteins at ~120 kDa and 
~80 kDa. However, after subjecting the total lysate to sequential immuno-precipitation, the FTVII treatment was 
found to introduce sLeX onto CD44 (~80 kDa), PSGL-1 (a homodimer of ~110–130 kDa monomers) and CD43 
(~110–130 kDa) (Fig. 4H), thereby creating the E-selectin ligands known as HCELL, PSGL-1/CLA, and CD4-E, 
respectively. (Each step in the sequential immunoprecipitation was shown to be complete by western blot analysis 
of each post stage of immunoprecipitation, see Supp Fig. 4) Importantly, no E-selectin-binding proteins remained 
in the lysate after successively removing these three proteins.
We next tested whether the enforced generation of E-selectin ligands had functional impact on the ability of 
the expanded nvTregs to adhere to endothelial cells or to suppress the activation of co-cultured non-regulatory 
CD4 T cells. As compared to cells treated with buffer only, the FTVII treated, expanded nvTregs exhibited a 
marked increase in their capacity to roll on and adhere to E-selectin-expressing vascular endothelial cells (Fig. 4I). 
Importantly, when tested in the typical Treg co-culture assay, which is not dependent on sLeX, the FTVII treat-
ment had no effect on the suppressive capacity of the tested Tregs. (Supp. Fig. 3B).
FTVII-treated nvTregs exhibit enhanced homing to an E-selectin-bearing tissue bed, and enhanced 
therapeutic activity in vivo. Next, we examined whether increasing the expression of surface E-selectin 
ligands affected the ability of the expanded nvTregs to home to inflamed tissues in vivo as would be expected. 
A xenogeneic model of aGVHD, in which tissue inflammation is initiated in NOD-scid IL2Rγnull (NSG) mice 
by the injection of human PBMC, was used to determine if buffer-treated or FTVII-treated expanded nvTregs 
exhibited differential tissue homing ability (see model in Fig. 5A). In using this model, the disease-initiating 
PBMCs and the potential disease-ameliorating Tregs were derived from the same donor, as a portion of the 
isolated PBMCs were injected to initiate tissue inflammation in the NSG mice (day 0), and a portion were used 
to FACS-sort nvTregs that were immediately placed in in vitro stimulation cultures. After two weeks of culture, 
the expanded nvTregs were harvested, tested for purity (FoxP3 stains, Supp. Fig. 3C), treated with buffer alone 
or with FTVII for exofucosylation, and then injected into mice that had previously received the autologous 
human PBMCs. To study short-term migration, the PBMC pre-sensitized mice were injected with buffer- or 
FTVII- treated, expanded nvTregs that had been labeled with CFSE or SNARF before injection. Twenty-four 
hours after injecting 5 × 106 of the different nvTreg populations, multiple tissues were excised and examined for 
the presence of the injected human cells, detected via expression of hCD45, SNARF and/or CFSE. As shown in 
Fig. 5B, the expanded nvTregs that had been treated with FTVII exhibited a significant preferential homing to an 
E-selectin-expressing tissue (bone marrow) as compared to cells treated with buffer only.
To determine whether administering nvTregs that had been exofucosylated would result in enhanced thera-
peutic activity, suboptimal numbers of expanded nvTregs were tested for their ability to inhibit PBMC-mediated 
xenogeneic GVHD. After administering a low number (1 × 105) of buffer-treated or FTVII-treated expanded 
nvTregs into mice that had previously received the autologous PBMCs, survival and weight loss were measured 
as indicators of aGVHD severity46. Under these conditions, mice injected with exofucosylated nvTregs exhib-
ited a significant reduction in disease severity as compared to mice that received the buffer-treated nvTregs or 
PBS (Fig. 6A). In contrast, by injecting optimal numbers (5 × 105) of mock-treated or FTVII-treated expanded 
nvTregs, the advantage conferred by the previous administration of exofucosylated Tregs was no longer detecta-
ble (Fig. 6B). Thus, the nvTregs treated with FTVII only exhibited their beneficial ability to inhibit disease when 
injected at suboptimal numbers. This suggests that the FTVII treatment conferred a potent in vivo amplification 
of Treg function – a finding that has direct implications for the problem of limiting cell numbers of Treg cellular 
therapies.
In addition to relating the administration of Tregs to disease activity as indicated by weight loss and pro-
longed survival46, we determined if the administration of the Treg therapeutic could also be shown to affect 
the expression of human pro-inflammatory cytokines by the disease initiating PBMCs. To perform these stud-
ies, RNA isolated from various aGVHD relevant tissues (taken on day 50) was interrogated for expression of 
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human cytokine genes by RT-PCR. (However, as this analysis could only be performed on mice that lived to 
day 50 post-transplant, there were limited numbers of samples from the mice exhibiting acute disease that had 
received only PBMCs and PBS.) The samples were examined for expression of human FoxP3, as well as the human 
pro-inflammatory cytokines IL-17 and TNFα, to determine if there was a relationship between disease activity 
(as indicated by body weight) and expression of these genes at this late time point. As shown in Fig. 6C, increased 
expression of human FoxP3 was detected in the intestine and bone marrow in the healthier, Treg-recipient mice 
as compared to the mice exhibiting weight loss. In contrast, the analysis of human IL-17 expression revealed the 
opposite result in which IL-17 expression was directly associated with disease activity (Fig. 6D). Lastly, there was 
no association between expression of TNFα (Fig. 6E) and GVHD severity.
Discussion
The ability to exploit Treg-based therapy for immunological diseases offers the exciting opportunity to establish 
immune homeostasis and/or enable tolerance without the attendant risks of infection and organ toxicities inher-
ent to pharmacologic immunosuppressants. Here we report the study and the functional comparison of specific 
human PBMC-derived Treg subpopulations that had been expanded in vitro. Our investigations focused on sev-
eral critical aspects of human Treg biology with intent to determine if any one subset might exhibit advantages 
in purity, lineage fidelity, migration capacility, and suppressive activity; features that would be requisite for opti-
mizing Treg therapeutics. In addition to offering information relevant for Treg therapeutic development, these 
data also shed light on fundamental aspects of Treg glycome biology. Specifically, although stimulated nvTregs 
mirror memTregs in suppressive ability, we observed that this stimulation does not induce the naïve Tregs to 
become bonafide memory Tregs. Instead, by maintaining their regulation of fucose-regulating enzymes, the in 
vitro expanded nvTregs retain their naïve expression of surface sLeX glycosylation. How the expression of fucose 
modifying enzymes is regulated when nvTregs transition into memory Tregs in vivo, is as yet unclear.
Over the years, human Tregs have been divided into many different subsets defined by the expression of 
various surface proteins and usually associated with distinct functional attributes. The most basic subdivi-
sion of human Tregs separates the CD4 + CD25hiCD12710 Tregs into memory or naïve populations by virtue 
of the expression of CD45RA (naïve) or CD45RO (memory). By studying the gene expression profiles in over 
40 reported Treg subset divisions, a recent study concluded that human naïve Tregs and DR+ memory Tregs 
truly represented distinct subsets47. As our primary goal in these studies was to determine whether distinct 
Treg subsets exhibited differential suitability for use as a cellular therapeutic, we tested the functional properties 
of human naïve, DR+ and DR− memory Treg subpopulations both after fresh isolation from blood and after 
in vitro expansion.
Figure 5. FTVII-Treated regulatory T cells traffic preferentially to bone marrow. (A) Depicts the schematic 
for model of xenogeneic graft vs host disease, noting the simultaneous use of PBMCs for disease initiation and 
initiation of nvTreg expansion cultures. (B) The ability of FTVII treatment to affect tissue migration was tested 
by co-injecting (i.v.) expanded nvTregs that were buffer or FTVII- treated, and differentially labeled with CFSE 
or SNARF, into NSG mice 14 days after the injection of 107 PBMCs. After 24 hours, the frequency of Tregs in 
the bone marrow, lung, spleen, and liver was determined by FACS as compared to the number of human cells 
in each tissue as determined by staining for human CD45. Data are shown as mean ± SEM. Significance was 
determined by Student’s t test (*P < 0.05).
www.nature.com/scientificreports/
1 0Scientific REpORTS |  (2018) 8:420  | DOI:10.1038/s41598-017-17981-z
One major consideration was that Treg-based therapeutics would require a large number of cells, and thus 
the ideal Treg source had to be highly proliferative. The total population of memory Tregs is known to include 
most of the Tregs that express sLeX and those that also exhibit the capacity to transition into pro-inflammatory 
cells that co-express IL-17 or IFNγ4,36. Here, we report that unlike the DR−mTregs, the vast majority of effector 
DR + mTregs express sLeX and exhibit strong transendothelial migration (TEM) ability, indicating that the most 
suppressive effector Tregs (DR+mTreg) are also the cells that are the most prone to enter tissues. Unfortunately, 
the data also indicate that the highly suppressive DR+mTregs are not a suitable therapeutic choice as, although 
these circulating “effector” Tregs exhibit the highest expression of sLeX, the strongest suppressive capacity, and 
the greatest ability to transmigrate across endothelium under remarkably high shear forces, they only constitute 
a small fraction of blood-resident Tregs and cannot be sufficiently or stably expanded in vitro. The fact that these 
cells are unable to proliferate may be a beneficial property in vivo, in that permitting unrestricted proliferation of 
highly suppressive Tregs in tissues could have deleterious effect(s) on the host.
In contrast, although the DR−mTregs were more proliferative than their DR+ counterparts, they too were not 
an ideal choice as they gave rise to cells that co-expressed pro-inflammatory cytokines and FoxP3. In contrast, 
the nvTregs were only weakly suppressive when tested ex vivo, but exhibited the greatest proliferative capacity, 
maintained the highest lineage fidelity with low pro-inflammatory plasticity (i.e., IL-17 production) and became 
markedly more suppressive after in vitro expansion. Yet, both the freshly-isolated and culture-expanded nvTregs 
were found to lack expression of α(1,3)-fucosyltransferases necessary for creation of sLeX motifs that mediate ini-
tial cell attachment to endothelium under hemodynamic shear. However, having found that the nvTregs express 
Figure 6. FTVII-treatment improves efficacy of adoptive Treg therapy for GVHD in NSG mice. (A) NSG mice 
that had been injected with PBMC 14d earlier were injected with PBS (PBMC only) or suboptimal numbers 
(1.0 × 105) of buffer- or FTVII- treated, expanded nvTregs/mouse (n = 6). The injection of FTVII-treated/
expanded nvTregs significantly reduced the weight loss that is indicative of xenogeneic GVHD severity in NSG 
mice46. (B) In contrast, when mice were given optimal (5.0 × 105) doses of buffer- or FTVII- treated nvTregs, 
all Treg injected mice showed similar rescue from disease. RNA, isolated from the intestine (top) and bone 
marrow (bottom) isolated from mice that were still viable on day 50 after receiving the indicated treatments 
was examined for expression of (C) FoxP3, (D) IL-17, and (E) TNF-α relative to B2M by real-time PCR. 
Correlation to weight loss as a measure of disease activity was determined by linear regression analysis. Data 
shown are mean ± SEM. Significance, determined by Student’s t test, is indicated by (*P < 0.05), (**P < 0.01), 
and (***P < 0.001).
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proteins decorated with sialyllactosamines, the acceptor trisaccharide which is modified by α(1,3)-linked fucose 
(by action of α(1,3)-fucosyltransferases) to produce sLeX, we reasoned that sLeX could be enforced on the nvTreg 
surface by exofucosylation using FTVII and donor nucleotide sugar (GDP-fucose). Treating the expanded sLeX 
negative nvTregs with the fucosyltransferase FTVII resulted in their expression of sLeX, had no adverse affects 
on their in vitro suppressive ability, and strongly enhanced their in vivo inhibition of aGVHD in the PBMC/NSG 
xenogeneic model. These results not only indicate that the expanded nvTreg are highly efficient in vivo, but also 
that if they were fucosylated, markedly less sLeX+ (fucosylated) nvTregs were needed to inhibit aGVHD com-
pared to the activity of the unfucosylated nvTregs. This finding suggests that reduced numbers of Tregs could be 
efficacious as a cellular therapy, if they are first α(1,3)-exofucosylated treated to enhance surface sLeX expression.
As current Treg trials indicate the need for improvement, strategies to enhance Treg function/fidelity 
may help to realize the promise of adoptive Treg therapy12. Our data show that by selecting a Treg population 
from adult PBMCs to be the source of therapeutic Treg development, it may be possible to generate autolo-
gous Treg therapeutics with the potential for long-term engraftment. A number of recent studies have reported 
attempts to utilize Tregs derived from 3rd party cord blood to clinically inhibit the effects of immune-mediated/
inflammatory diseases48,49, including a study inducing selectin ligands on the surface of these cells50. Yet, cord 
blood-derived Tregs are less suppressive than those from adult blood51. Furthermore, although Treg suppression 
is MHC-independent52, if the goal of the therapeutic is to induce long-term Treg engraftment, T-cell/Treg engraft-
ment has been shown to require autologous MHC in the antigen presenting cell compartment53. This would indi-
cate that cellular therapeutics derived from allogeneic third party PBMC- or cord blood- derived Tregs may only 
satisfy short-term requirements for Treg suppression in vivo. In contrast, Treg engraftment may be more robust 
and functionally potent if the Treg cellular therapeutic was either derived from the expansion of patient-derived 
autologous Tregs, or, in cases of allogeneic bone marrow transplantation (HSCT), Tregs propagated from PBMCs 
derived from the hematopoietic stem cell donor. Accordingly, we focused here on examining the therapeutic 
suitability of adult PBMC-derived Treg subsets to increase the feasibility of providing autologous Treg cellular 
therapies to patients suffering from autoimmune diseases or to recipients of HSCT suffering from aGHVD.
Collectively, our findings highlight the use of culture-expanded adult PBMC-derived naïve Tregs in combi-
nation with cell surface glycan engineering to enforce sLeX expression to direct the administered Tregs to sites 
where they are needed. Surprisingly, our data also suggests that memory Tregs should be purposefully excluded 
from the source used to derive the Treg therapeutic, as the memory Treg subsets exhibit increased propensity 
to become ex-Tregs or pro-inflammatory cells. Thus, in addition to adding to our knowledge of human Treg 
immunobiology and human Treg glycobiology, the data provide a readily translatable roadmap for optimizing 
Treg-based therapeutics.
Methods
PBMC and Human Treg isolation. Peripheral blood was drawn from healthy individuals after informed 
consent, with approval by the Institutional Review Board at the Brigham and Women’s Hospital. All experiments 
were performed in accordance with the relevant guidelines and regulations in these protocols. Peripheral Blood 
Mononuclear Cells (PBMCs) were isolated with Ficoll Hypaque (GE Healthcare) gradient centrifugation. CD4+ 
T cells, isolated by human CD4 T cell Isolation kit (negative selection, Miltenyi Biotec), were stained with anti-
bodies to CD25 (clone M-A251), CD127 (clone HIL-7R-M21), CD45RA (clone HI100) and HLA-DR (clone 
G46–6) from BD Biosciences, and sorted on a FACSAria (BD Biosciences). nvTreg (CD45RA+), and memory 
(CD45RA−) Tregs are isolated as CD25HI and CD127LO, while the HLA-DR− and HLA-DR+ Treg differ by HLA-
Class II expression. Memory Tresp (non –regulatory memory CD4 T-cells) are isolated as CD25LO, CD127HI, and 
CD45RA−.
In vitro Treg expansion cultures. Freshly isolated, blood-derived T cell populations were cultured in 
96-well round bottom plates (Costar) coated with 0.5 ug/ml anti-CD3 (UCHT-1, eBioscience) with irradiated 
antigen presenting cells (iAPC, PBMCs depleted of T cells via anti-CD2-beads from Dynal/Invitrogen) and 
0.25 ug/ml anti-CD28 (clone 28.2 eBioscience) in RPMI-1640 medium (Life Technologies) supplemented with 
10% FBS (Life Technologies) and 20 U/ml rhIL-2. Confluent wells were split into new plates and IL-2 containing 
media was supplemented every 2–3 days. After two weeks, purity (expression of FoxP3high) was tested by flow 
cytometry using anti-FoxP3 (clone 206D, BioLegend) and the intracellular FoxP3 staining kit (Biolegend).
Co-culture suppression assays. Freshly isolated Tresp cells (2.5 × 103/well, CFSE labeled [Invitrogen]) 
were co-cultured with 1.25 × 103/well Treg, iAPCs (1 × 104/well) at a 1:1/2 ratio, in triplicates in wells coated 
with 0.2μg anti-CD3 (UCHT-1, eBioscience), or in wells given beads coupled with anti-CD3 (UCHT1, BD 
BioSciences) and anti-CD2 (RPA-2, BioSciences) or anti-CD28 (28.2, BioSciences) (tosyl-activated Beads from 
Dynal. Suppressive capacity was determined after 4 or 5 days by analyzing CFSE dilution on a BD Canto II with 
proliferation index analysis using FlowJo (Treestar).
Antibodies, flow cytometric analysis and immunoprecipitation. Flow cytometry was performed 
on a FACS Canto II (BD Biosciences) and analyzed using FlowJo Software (Treestar). Cells were stained with 
antibodies to CD3, CD4 (OKT4), CXCR4 (12G5), VLA-4 (9F10) and CD15s (CSLEX1) from BD biosciences, 
and HECA452, CD45 (2D1), CD44 (BJ14), CD162 (KPL-1), CD43 (CD43-10G7), and FoxP3 (206D) from 
Biolegend. Staining with mouse E-selectin Ig chimera (RnD Systems) was detected with either anti-His FITC 
(Bethyl Laboratories) for flow cytometry or secondary rat anti-mouse CD62E (BBIG-E4, RnD Systems) followed 
by goat anti-rat IgG HRP (Southern Biotech) for western analyses.
Lysates were made from cells by sonication/vortexing in buffer containing 50 mM Tris, 150 mM NaCl, 20 ug/ml 
phenylmethanesulfonyl fluoride (PMSF), 0.2% NaN3, protease inhibitor cocktail (Roche), 2% NP40, and 
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0.2% SDS. Precleared lysates were incubated antibodies to CD43 (1G10, L60, BD Biosciences; 20819, Santa 
Cruz Biotechnology), PSGL-1 (KPL-1, BD Biosciences; 20929, Santa Cruz Biotechnology), or CD44 (515, BD 
Biosciences; 2C5, RnD systems). Protein was immunoprecipitated with Protein-G agarose (Life Technologies). 
Western Blots were run with Reducing SDS-PAGE gels (Bio-Rad).
Exofucosylation. Cells were treated with fucosyltransferase VII (FTVII) or buffer-only at 37 °C for 60 min-
utes. Tregs were resuspended at 3 × 106 cells/30 ul in HBSS with 2 ug FTVII (RnD Systems), 10 mM Hepes, 
0.1% Human Serum Albumin, and 1 mM GDP fucose (Carbosynth). Treatment success was determined by flow 
cytometry with HECA452 mAb (Biolegend).
Parallel Plate Flow Chamber. Human umbilical vein endothelial cells (HUVEC, Lonza) were cultured in 
EGM-2 media (Lonza) in Bioflux microfluidic chambers coated with 250 ug/ml fibronectin (BD Biosciences). 
Four hours prior to rolling assay, cells were activated with 40 ng/ml TNFα (RnD Systems). Different cell subsets 
were infused into the chamber in a bolus of 10 × 106/ml – shear stress was applied from 0.5–8 dynes/cm2 and the 
number of rolling/adherent events relative to counted cells in initial field of view was counted (to normalize for 
rolling capacity on endothelium).
GVHD model and homing assays. NOD/SCID IL-2Rγnull mice (NSG, Jackson Laboratories, 4–8 weeks 
of age) were given intraperitoneal (IP) PBMCs (10 × 106) from healthy donors. 14 days later, mice were given 
expanded nvTregs that had been either buffer- or FTVII-treated by intravenous (IV) injection. The mice were 
monitored until day 50 for signs of GVHD – weight loss, hunched posture, hair loss, etc. At day 50, or at >20% 
weight loss, mice were sacrificed and bone marrow and intestine were harvested for analysis by flow cytometry 
and PCR. Mice were not included in the analysis if they failed engraftment of the injected PBMCs as indicated by 
fewer than 1 × 104 human cells in the bone marrow, spleen or lung on d50. The homing assays were performed on 
NSG mice given PBMCs 14 days prior to injection of the labeled Treg populations. The mice were subsequently 
injected (i.v.) with buffer-treated and FTVII-treated naïve expanded regulatory T cells that were differentially 
stained with either CFSE or SNARF (Life Technologies). (The staining dyes were alternated in repeat experiments 
as a control). At 24 hours, mice were sacrificed and single cell suspensions of spleen, bone marrow, lung and 
liver were analyzed for frequency of CFSE+ or SNARF+ cells within the population of cells expressing hCD45 
(Biolegend). All animal methods and experimentations were performed in accordance to our accepted protocols 
following the guidelines outlined by the Harvard Medical School Center for Comparative Medicine Institutional 
Animal Care and Use Committee-approved protocols.
Transmigration. HUVEC cells (Lonza) were cultured in EBM-2 media with EGM-2 supplements (Lonza) in 
5.0 micron transwells (Costar) in 24 well plates overnight. Transwells were pretreated with 100 ug/ml Fibronectin 
(BD Biosciences) for 2 hours at 37 °C. HUVECs were activated for 4 hours with 40 ng/ml TNFα (RnD Systems) 
and placed in wells with lower well containing 125 ng/ml SDF-1. Tregs were overlayed onto the HUVEC layer and 
incubated at 37 °C for 12 hours. Cells in the lower chamber were counted by flow cytometry and normalized with 
counting beads to cell input (based on cell number in adjacent, transwell-free lane) – subtracting the number of 
cells migrating through unactivated HUVEC.
PCR analysis. mRNA was isolated using RNeasy Microkit (Qiagen) from 10% of each mouse organ and ~100 
ul whole blood. cDNA was generated using VILO cDNA Synthesis Kit (Life Technologies). Realtime PCR was 
performed using the Taqman fast PCR master mix (Life Technologies), with primers for Beta-2 Microglobulin, 
IL-17, TNFα, FoxP3 and IFNγ (Life Technologies). Fucosyltransferase and fucosidase experiments were run 
with oligos to FUT4 (Origene), FUT754, and FUC1α55, with SYBR Select Master Mix (Life Technologies). 
Oligonucleotide sequences for the RT-PCR detection of FUT4, FUT7, and FUC1 are shown in Supp Table 1. All 
experiments performed on a Lightcycler 480 (Roche) and analyzed using StepOne software (Life Technologies).
Pronase Treatment. Cells were treated with 1 mg/ml Pronase (Roche) in HEPES Buffer at 37 °C for 30 min.
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